Kura Oncology (KURA) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.78

Estimate

-$0.81

Surprise

+3.8%

Revenue (period 2026-09-30)

$22.8M

Score today

5.4/10

Revenue source: xbrl.

Kura Oncology (KURA) reported a narrower loss than forecast — adjusted EPS of -$0.78 against the -$0.81 estimate (a 3.8% beat on a still-unprofitable quarter).

• Kura Oncology Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-10
• Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed — benzinga, 2026-11-10
• Kura Oncology Q3 Cash, Equivalents & ST Investments $492.1M; Says Cash Runway Extends Beyond KOMET-017 Topline Results I — benzinga, 2026-11-10

TrendMatrix currently rates KURA Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +3.8% surprise compares with a -53.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$7.57

Price target

$10.74

Stop

$7.04

Upside to target

+41.9%

Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$673.4M

P/E (fwd)

-3.2

52-week range

$6.75–$13.90

Off 52-week high

45.5%

RSI (14)

32

Volume vs avg

1.14×

Score today

5.4/10